Compare Medpace Holdings Inc (MEDP) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Verisign, Inc. — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Verisign, Inc. trades at $304.06 (market cap $26.92B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.09% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Verisign, Inc. for 123 Days on average.
| MEDP | VRSN | |
|---|---|---|
Market Cap | $16.82B | $26.92B |
Volume | 223,093 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $630.19 | $310.00 |
52-Week Low | $393.42 | $211.49 |
Typical Hold Time | 14 Days | 123 Days |
Enterprise Value | $16.44B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
VeriSign (VRSN) trades at $305.53, up 3.84% today, with a bullish technical outlook and strong institutional buying. The company reported solid Q2 2026 results with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations slightly. High profitability is evident with a net income margin near 50%, but valuation multiples like P/E of 32.33 are elevated. Recent news includes an antitrust lawsuit and insider selling by the CEO, while major institutions like BlackRock have increased stakes.
The stock offers growth potential from domain registration increases and AI-driven demand, with a consensus price target of $348 implying 14% upside. Risks include regulatory scrutiny from the antitrust case, high debt levels, and premium valuation. Analyst sentiment is positive with 60% buy ratings, but investors should monitor Q3 2026 earnings on October 22 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
